In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Reckitt Benckiser buys Paras Pharmaceuticals for $726mm

Executive Summary

Reckitt Benckiser PLC has agreed to pay $726mm (INR32.6bn) for private Indian OTC and personal care company Paras Pharmaceuticals Ltd. The price is about 8.1x Para's 2010 sales of $90mm. The deal is the second-largest Indian pharma acquisition this year, behind Abbott Laboratories' $3.72bn buy of Piramal Healthcare's branded generics business.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies